Effects Of Epigallocatechin-3-gallate (EGCG) On Colon Cancer In Vivo And Notch Signaling Pathway

【Objectives】To study the anticancer effect of different doses of epigallocatechin-3-gallate (EGCG) on colon cancer with subcutaneous translocation fluorescence in situ animal model and Notch signaling pathway related genes.【Method】Using the human colon cancer cell line HT-29to establish the colon cancer subcutaneous translocation fluorescence in situ transplantation model. Thirty-nine nude mice were randomly divided into four groups, which were saline control group and5,10,20mg/kg EGCG groups. All the mice except saline control group received EGCG for14days. After that, we observed whether the primary tumor has metastasis and calculate the tumor volume. We derived the primary tumor after2,4and6weeks, then observed the tumor cell apoptosis by TUNEL and examined the Notch1、Notch2gene expression by RT-PCR.【Results】Using doses of5,10and20mg/kg EGCG to treatment, we found the tumor growth of treatment group was significantly lower than others at14,28and35days (P<0.05); In the5mg/kgEGCG group, apoptosis was increased significantly, and the expressions of Notch1and Notch2gene were raised. The difference between5mg/kgEGCG group and control group was significant (P<0.05). But comparison between the three treatment groups had no significant difference.【Conclusion】EGCG can significantly inhibit tumor growth of colorectal cancer with subcutaneous translocation fluorescence in situ colon cancer animal model. It promotes tumor cell apoptosis and increases Notch1and Notch2expression. Whereas the relationship between effect and dose still needs to be explored in further.